Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial
| Title | Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial |
|---|---|
| Description | This abstract will be open to public at ASCO 2023 Annual Meeting. |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA012345 |
| Release Date | 2023-06-02 |
| Submitter | Changli Wang (wangchangli309@163.com) |
| Organization | Tianjin Cancer Hospital |
| Submission Date | 2023-03-08 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX003263-01 | 816 Table_ ASCO2023 | 1 | Biomarker Data | 112.3 KB | rar | 0 | Controlled |